Editor's View: Shifting horizons in dementia care—from prevention and screening to real-world clinical practice

Résumé fourni par la source

Dementia represents one of the most significant challenges to global public health, health systems and social care frameworks in the 21st century [1]. Historically, clinical models heavily focussed on late-stage management, where the focus was entirely reactive. However, modern geriatric medicine is driving a profound paradigm shift. This new perspective frames cognitive decline not as an isolated, inevitable consequence of ageing, but as a complex, multifaceted trajectory shaped by lifestyle behaviours, systemic physiological stressors, clinical care environments and socio-geographical factors as recently pointed out by the World Health Organization (details here: https://www.who.int/publications/i/item/9789240123557). The June 2026 issue of Age and Ageing beautifully highlights this comprehensive approach. Rather than evaluating dementia through a narrow lens, the recent literature offers an integrated view that spans the entire continuum of care. The selected papers for this month’s digest investigate early non-pharmacological interventions, cost-effectiveness models for prevention, novel digital screening methods and under-recognised systemic risk factors. Furthermore, they delve into the harsh clinical realities of managing medication safety, navigating systemic barriers in under-served communities and confronting the profound ethical dilemmas of advanced cognitive decline. Together, these articles challenge clinicians to transition from siloed care structures toward proactive, holistic and deeply empathetic models of geriatric practice. In the realm of cognitive preservation, non-pharmacological interventions are increasingly recognised as primary strategies for maintaining function. Li et al. [2], for example, contribute substantially to this body of evidence through a comprehensive systematic review and meta-analysis evaluating the efficacy of traditional Chinese exercises on cognitive function in older adults. Examining data from multiple randomised controlled trials, the authors demonstrate that structured, mind–body exercises—such as Tai Chi and Qigong—exert a significant positive impact on global cognitive performance and specific executive functions. The dual cognitive and motor demands of these exercises may promote neuroplasticity and enhance prefrontal cortex activation. Because these interventions are low-cost, scalable and physically safe, they represent an ideal, accessible community-based tool for supporting intrinsic capacity and delaying the onset of cognitive decline [2]. While clinical efficacy is paramount, implementing large-scale lifestyle intervention programmes requires economic validation to persuade public health stakeholders that, often, do not support large-scale interventions to prevent dementia. The APPLE-Tree programme (Active Prevention in People at risk of dementia through Lifestyle, behaviour change and Technology to build Resilience) conducts a meticulous cost-utility and cost-effectiveness analysis of this multi-component intervention [3]. The findings reveal that combining lifestyle changes, behaviour modifications and supportive digital technology is not only clinically viable but also highly cost-effective [3]. By explicitly demonstrating that early lifestyle-driven resilience programmes can reduce long-term care expenditures and optimise quality-adjusted life years, this trial provides a robust financial blueprint for embedding dementia prevention frameworks into national healthcare strategies. Early detection remains a major clinical bottleneck, as many individuals with mild cognitive impairment or early-stage dementia go unnoticed during routine consultations [4]. Nie et al. offer a technological solution to this challenge by utilising a Generalised Additive Models for Location, Scale and Shape (GAMLSS) approach to evaluate a novel digital dementia screening tool in China [5]. This innovative, two-step cognitive self-assessment platform dynamically profiles an individual’s cognitive performance based on age, education and specific digital interaction patterns. The GAMLSS methodology allows for highly refined, individualised scoring boundaries, significantly enhancing diagnostic accuracy. This study underscores the immense potential of digital health tools to democratise early cognitive screening, allowing patients and families to securely flag early changes from home, thereby prompting timely clinical evaluations. The staggering scale of the screening gap is powerfully illustrated in a short report by Miguel et al., which provides critical estimates of undetected dementia in Brazil [6]. Using robust population-based datasets, the authors reveal an alarmingly high prevalence of older individuals living with completely undiagnosed cognitive impairment. This undetected burden is disproportionately concentrated in socioeconomically vulnerable populations, driven by limited specialist availability and pervasive public stigma. Miguel’s work serves as an urgent wake-up call for global geriatrics: developing sophisticated digital screening tools is insufficient if public health infrastructure fails to deploy them equitably [6]. Bridging this gap requires an aggressive expansion of community-based screening programmes tailored specifically to middle- and low-income countries in which dementia prevalence and incidence are exponentially increasing [7]. A modern understanding of dementia recognises that the brain does not age in isolation from the rest of the body. In a fascinating nationwide propensity score-matched cohort study, Underwood et al. investigate the long-term risk of developing dementia after a bloodstream infection [8]. Their findings uncover a striking, persistent association: surviving an episode of severe systemic bacteraemia or sepsis is linked to a significantly elevated risk of subsequent dementia diagnoses [8]. This association suggests that severe systemic inflammation can compromise the blood–brain barrier, accelerate neuroinflammatory cascades and permanently injure vulnerable cerebral networks. For practicing clinicians, this research highlights the critical importance of closely monitoring sepsis survivors for long-term cognitive changes, shifting how we conceptualise the systemic triggers of neurodegeneration. Moreover, as reported by our team lately in 2025, to prevent infections, for example, with vaccinations, could delay the onset of dementia in older people [9]. Once dementia is established, navigating pharmacological safety becomes an extraordinarily delicate balancing act, particularly in a period in which the use of potentially new medications, such as monoclonal antibodies, is still debated. Yu et al. explore this terrain through a systematic review and meta-analysis analysing the impact of structured medication management interventions on healthcare utilisation in people living with dementia [10]. Pharmacological care for this population is notoriously complex due to high rates of multi-morbidity and polypharmacy. The authors show that multidisciplinary medication reviews successfully lower inappropriate prescribing and significantly reduce preventable healthcare utilisation, including emergency department presentations and unplanned hospitalisations [10]. This imperative for pharmacological caution is reinforced by Newby and colleagues [11], who utilise a high-throughput sequence symmetry analysis to uncover dangerous prescribing cascades associated with acetylcholinesterase inhibitors (AChEIs). AChEIs are standard symptomatic therapies for Alzheimer’s disease, but their cholinergic side effects—such as urinary urgency or gastrointestinal distress—are frequently misdiagnosed as entirely new medical conditions. This misinterpretation leads to the inappropriate initiation of secondary medications, such as anticholinergic bladder drugs, which directly counteract the benefits of the dementia therapy and exacerbate cognitive decline. Recognising these specific prescribing cascades

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.